Multiple Sclerosis News and Research RSS Feed - Multiple Sclerosis News and Research

Multiple sclerosis (MS) is a severe autoimmune disease of the central nervous system that affects the brain and spinal cord, causing problems with muscle movement, balance and vision.

In MS, the protein coating called myelin, which protects nerves and helps electrical signals travel from the brain to the rest of the body, is damaged. The immune system, which usually fights infection, mistakes myelin for a foreign body and attacks it, stripping it from around the nerves. Exactly what causes this abnormal immune response is unclear, but research suggests a combination of both genetic and environmental factors.

The damaged myelin disrupts the transfer of nerve signals which may slow down, become distorted or stop altogether. This can cause severe symptoms ranging from vision loss through to muscle stiffness, loss of control over muscle movement, difficulties with balance and poor co-ordination.

Around 100,000 people in the UK have MS and it affects about three times as many women as men. The usual age at which diagnosis occurs is around 30, however, symptoms often first develop between the ages of 15 and 45.

Currently, there is no cure for MS but therapeutic approaches such as physiotherapy and steroid injections are used to manage the condition and ease symptoms.
BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today reported several new customer disclosures on the use of the Company's CryoStor and HypoThermosol biopreservation media products in pre-clinical validation projects and clinical trials at the recent International Society for Cellular Therapy (ISCT) conference. [More]
FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

FDA approves Actavis ANDA for guaifenesin/pseudoephedrine tablets to relieve chest congestion

Actavis plc and its partner Perrigo Company plc announced today that Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the U.S. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® D tablets. [More]
Doctor Evidence to contribute valuable clinical data to IBM Watson's oncology solutions, developer ecosystem

Doctor Evidence to contribute valuable clinical data to IBM Watson's oncology solutions, developer ecosystem

Today, Doctor Evidence, a clinical health research data provider, announced a content partnership with IBM Watson to contribute valuable clinical cancer research content to Watson's oncology solutions and developer ecosystem. [More]
Tackling comorbidities could improve MS survival

Tackling comorbidities could improve MS survival

Survival of patients with multiple sclerosis is still reduced, despite recent improvements, say researchers. [More]
Novel discovery offers new insight into why women more likely than men to develop MS

Novel discovery offers new insight into why women more likely than men to develop MS

An innocent mistake made by a graduate student in a Northwestern Medicine lab (she accidentally used male mice instead of female mice during an experiment) has led scientists to a novel discovery that offers new insight into why women are more likely than men to develop autoimmune diseases such as multiple sclerosis (MS). [More]
People with MS have much greater risk of dying younger compared to people without MS

People with MS have much greater risk of dying younger compared to people without MS

New research suggests people with multiple sclerosis (MS) may have double the risk of dying early compared to people without MS, with those younger than 59 at a three times higher risk. The study is published in the May 27, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
St. Luke’s, Greater Delaware Valley Chapter of MS Society partner to improve MS care

St. Luke’s, Greater Delaware Valley Chapter of MS Society partner to improve MS care

St. Luke’s Neurology Associates and the Greater Delaware Valley Chapter of the National Multiple Sclerosis Society agreed to a “Partners in MS Care” partnership. [More]

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

World MS Day was created by the Multiple Sclerosis International Foundation (MSIF) in 2009 to raise global awareness of MS... [More]
UC San Diego Health System designated as Center of Excellence for Huntington's disease

UC San Diego Health System designated as Center of Excellence for Huntington's disease

The Huntington's Disease Clinical Research Center at UC San Diego Health System has been designated a Center of Excellence by the Huntington's Disease Society of America. UC San Diego was one of only 29 centers nationwide to receive this prestigious designation, which recognizes centers for their elite multidisciplinary approach to Huntington's disease care and research. [More]
New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA. [More]
Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression. [More]
New research points to potential therapeutic target for treating multiple sclerosis

New research points to potential therapeutic target for treating multiple sclerosis

New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty "brake" within immune cells, a brake that should be controlling the inflammation. This points to a potential target for developing new therapies to treat multiple sclerosis and could have important implications for other autoimmune diseases, such as the colon disease colitis and the chronic skin condition atopic dermatitis. [More]
fMRI reflects interactions between brain regions

fMRI reflects interactions between brain regions

Tübingen neuroscientists have made an important advance in studying the human brain with functional magnetic resonance imaging (fMRI). [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Regulatory T cells can cure inflammatory diseases, shows research

Regulatory T cells can cure inflammatory diseases, shows research

Scientists at The University of Manchester have made an important discovery about an immune cell which is already being used in immunotherapy to treat diseases such as type I diabetes. [More]
TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

Interferon proteins are normally considered virus-fighters, but scientists at The Scripps Research Institute have found evidence that one of them, interferon beta (IFNβ), has an immune-suppressing effect that can help some viruses establish persistent infections. [More]
Major breakthrough in understanding development of type 1 diabetes

Major breakthrough in understanding development of type 1 diabetes

Joslin researchers have uncovered the action of a gene that regulates the education of T cells, providing insight into how and why the immune system begins mistaking the body's own tissues for targets. The gene, Clec16a, is one of a suite of genes associated with multiple autoimmune disorders, suggesting it is fundamental to the development of autoimmunity. [More]
UAB opens third multidisciplinary clinic for transverse myelitis

UAB opens third multidisciplinary clinic for transverse myelitis

Mike Jezdimir knows firsthand how hard it is to get appropriate medical treatment for his condition, a disease of the spinal cord called transverse myelitis. He has had it for 48 years, since he was 17. TM is fairly uncommon, and many physicians rarely encounter it. Treatment options are limited. [More]

Perrigo announces acquisition of Patheon's Mexican operations for $34 million

Perrigo Company plc announced today that it has acquired the Mexican operations of Durham, North Carolina-based Patheon for $34 million in cash. [More]
Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

In a major advance in the field of neuropsychiatry, researchers in the Vollum Institute at Oregon Health & Science University have illuminated how cocaine and amphetamines disrupt the normal functioning of the dopamine transporter in the brain. [More]
Advertisement
Advertisement